Area of research
Nephrology · Nutrition and Dietetics
Research interest
Research interests include Parathyroid Disorders and Treatments, Magnesium in Health and Disease, Vitamin D Research Studies, and Fibroblast Growth Factor Research.
Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure.
Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial.
Fibroblast Growth Factor 23 Trajectories in Children and Association with CKD Progression: The CKD in Children Study.
Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease
Higher versus Lower Phosphate Targets for Patients Undergoing In-Center Hemodialysis
Effects of Lowering Dietary Phosphorus Additive Intake on Mineral Metabolism in Adults with and without CKD.
Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney Failure.
Higher versus Lower Phosphate Targets for Patients Undergoing In-Center Hemodialysis: A Randomized Controlled Trial.
Clinical evidence for independent regulation of vitamin D by intestinal CYP24A1. Reply.
FGF23 and klotho at the intersection of kidney and cardiovascular disease.
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Intestinal Cyp24a1 regulates vitamin D locally independent of systemic regulation by renal Cyp24a1 in mice
Calcium and Phosphate Disorders: Core Curriculum 2024.
Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study
Intestinal Cyp24a1 regulates vitamin D locally independent of systemic regulation by renal Cyp24a1 in mice
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial.
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD.
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study
Targeting Gut Microbiome With Prebiotic in Patients With CKD: The TarGut-CKD Study
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial
Renal proximal tubule cells: power and finesse.
Plasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease.
Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study.
Associations of FGF23 with 10-Year Change in eGFR and UACR and with Incident CKD in the CARDIA Cohort.
The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial